Scientific article
Open access

Impact of rosuvastatin on atherosclerosis in people with hiv at moderate cardiovascular risk: a randomised, controlled trial

Published inAIDS, vol. 35, no. 4, p. 619-624
Publication date2021-03-15

Background: People living with HIV-1 (PLHIV) are at increased risk for cardiovascular disease.

Objective: This study aimed to determine if PLHIV would benefit from starting statins at a lower threshold than currently recommended in the general population.

Design: A double-blind multicentre, randomised, placebo-controlled trial was performed.

Methods: Participants (n = 88) with well controlled HIV, at moderate cardiovascular risk (Framingham score of 10-15%), and not recommended for statins were recruited from Australia and Switzerland. They were randomized 1 : 1 to rosuvastatin (n = 44) 20 mg daily, 10 mg if co-administered with ritonavir/cobicistat-boosted antiretroviral therapy, or placebo (n = 40) for 96 weeks. Assessments including fasting blood collection and carotid--intima media thickness (CIMT) were performed at baseline, and weeks 48 and 96. The primary outcome was the change from baseline to week 96 in CIMT (clinicaltrials.gov: NCT01813357).

Results: Participants were predominantly men [82 (97.6%); mean age 54 years (SD 6.0)]. At 96 weeks, there was no difference in the progression of CIMT between the rosuvastatin (mean 0.004 mm, SE 0.0036) and placebo (0.0062 mm, SE 0.0039) arms (P = 0.684), leading to no difference in CIMT levels between groups at week 96 [rosuvastatin arm, 0.7232 mm (SE 0.030); placebo arm 0.7785 mm (SE 0.032), P = 0.075].Adverse events were common (n = 146) and predominantly in the rosuvastatin arm [108 (73.9%)]. Participants on rosuvastatin were more likely to cease study medication because of an adverse event [7 (15.9%) vs. 2 (5.0%), P = 0.011].

  • Atherosclerosis / complications
  • Atherosclerosis / drug therapy
  • Australia
  • Cardiovascular Diseases / prevention & control
  • Carotid Intima-Media Thickness
  • Double-Blind Method
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • Heart Disease Risk Factors
  • Humans
  • Male
  • Middle Aged
  • Risk Factors
  • Rosuvastatin Calcium
  • Switzerland
  • Treatment Outcome
Research group
  • SNSF -
Citation (ISO format)
TREVILLYAN, Janine M et al. Impact of rosuvastatin on atherosclerosis in people with hiv at moderate cardiovascular risk: a randomised, controlled trial. In: AIDS, 2021, vol. 35, n° 4, p. 619–624. doi: 10.1097/QAD.0000000000002764
Main files (2)
Article (Accepted version)
Article (Published version)
Secondary files (3)
ISSN of the journal0269-9370

Technical informations

Creation02/23/2022 2:40:00 PM
First validation02/23/2022 2:40:00 PM
Update time03/16/2023 7:04:21 AM
Status update03/16/2023 7:04:17 AM
Last indexation05/06/2024 11:14:27 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack